Bioson Pharmaceutical announced on the 30th that it will begin joint development with iCure, a company specializing in patch-type drug development, to develop the non-narcotic analgesic Opiranserin (VVZ-149) as a transdermal delivery formulation.
The two companies will apply iCure's transdermal drug delivery system (TDDS) technology to Opiranserin, a non-narcotic analgesic developed by Bioson using its multi-target new drug discovery platform technology, to develop an innovative new formulation of a novel drug. TDDS is a technology that delivers drugs into the body by attaching a film-type transdermal formulation to the skin.
Bioson Pharmaceutical expects that using iCure's technology will enable the development of a new formulation of Opiranserin transdermal delivery that minimizes drug side effects while maximizing efficacy.
Opiranserin is the world's first multi-receptor targeted non-narcotic analgesic. It simultaneously inhibits Glycine Transporter 2 (GlyT2) and Serotonin Receptor 2a (5HT2a), which are directly involved in generating pain signals in peripheral nociceptors such as skin, muscles, ligaments, and joints.
Previously, Bioson Pharmaceutical applied for approval from the Korean Ministry of Food and Drug Safety for a non-narcotic analgesic injection formulation developed with Opiranserin under the product name 'Eunapraju.' The indication for Eunapraju is moderate to severe acute pain, including postoperative pain.
A representative from Bioson Pharmaceutical stated, "Through this joint research, we aim to successfully develop Opiranserin in a new formulation to become an alternative treatment for musculoskeletal pain. We expect that the Opiranserin transdermal delivery formulation will improve patient medication compliance and expand the market to include patients requiring pain management not only after surgical procedures but also for non-surgical treatments."
Meanwhile, iCure has commercialized the world's first donepezil patch for Alzheimer's dementia treatment using TDDS technology.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
